🚀 VC round data is live in beta, check it out!
TuHURA Biosciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for TuHURA Biosciences and similar public comparables like Vistin Pharma, Nykode Therapeutics, Vytrus Biotech, Coya Therapeutics and more.
TuHURA Biosciences Overview
About TuHURA Biosciences
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
Founded
1995
HQ
Employees
19
Website
Sectors
Financials (FY)
EV
$100M
TuHURA Biosciences Financials
TuHURA Biosciences reported last fiscal year revenue of — and negative EBITDA of ($17M).
In the same fiscal year, TuHURA Biosciences generated ($17M) in EBITDA losses and had net loss of ($22M).
Revenue (LTM)
TuHURA Biosciences P&L
In the most recent fiscal year, TuHURA Biosciences reported revenue of — and EBITDA of ($17M).
TuHURA Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($17M) | XXX | XXX | XXX |
| Net Profit | ($30M) | XXX | ($22M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
TuHURA Biosciences Stock Performance
TuHURA Biosciences has current market cap of $102M, and enterprise value of $100M.
Market Cap Evolution
TuHURA Biosciences' stock price is $1.80.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $100M | $102M | 0.0% | XXX | XXX | XXX | $-0.38 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTuHURA Biosciences Valuation Multiples
TuHURA Biosciences trades at (5.7x) EV/EBITDA.
TuHURA Biosciences Financial Valuation Multiples
As of March 18, 2026, TuHURA Biosciences has market cap of $102M and EV of $100M.
Equity research analysts estimate TuHURA Biosciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
TuHURA Biosciences has a P/E ratio of (3.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $102M | XXX | $102M | XXX | XXX | XXX |
| EV (current) | $100M | XXX | $100M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (5.7x) | XXX | XXX | XXX |
| EV/EBIT | (3.3x) | XXX | (5.7x) | XXX | XXX | XXX |
| P/E | (3.4x) | XXX | (4.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (6.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified TuHURA Biosciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
TuHURA Biosciences Margins & Growth Rates
TuHURA Biosciences' revenue in the last fiscal year grew by —.
TuHURA Biosciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (40%) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
TuHURA Biosciences Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Vistin Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Nykode Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Vytrus Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Coya Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Fortress Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
TuHURA Biosciences M&A Activity
TuHURA Biosciences acquired XXX companies to date.
Last acquisition by TuHURA Biosciences was on XXXXXXXX, XXXXX. TuHURA Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by TuHURA Biosciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTuHURA Biosciences Investment Activity
TuHURA Biosciences invested in XXX companies to date.
TuHURA Biosciences made its latest investment on XXXXXXXX, XXXXX. TuHURA Biosciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by TuHURA Biosciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout TuHURA Biosciences
| When was TuHURA Biosciences founded? | TuHURA Biosciences was founded in 1995. |
| Where is TuHURA Biosciences headquartered? | TuHURA Biosciences is headquartered in United States. |
| How many employees does TuHURA Biosciences have? | As of today, TuHURA Biosciences has over 19 employees. |
| Who is the CEO of TuHURA Biosciences? | TuHURA Biosciences' CEO is James A. Bianco. |
| Is TuHURA Biosciences publicly listed? | Yes, TuHURA Biosciences is a public company listed on Nasdaq. |
| What is the stock symbol of TuHURA Biosciences? | TuHURA Biosciences trades under HURA ticker. |
| When did TuHURA Biosciences go public? | TuHURA Biosciences went public in 2024. |
| Who are competitors of TuHURA Biosciences? | TuHURA Biosciences main competitors are Vistin Pharma, Nykode Therapeutics, Vytrus Biotech, Coya Therapeutics. |
| What is the current market cap of TuHURA Biosciences? | TuHURA Biosciences' current market cap is $102M. |
| Is TuHURA Biosciences profitable? | No, TuHURA Biosciences is not profitable. |
| What is the current net income of TuHURA Biosciences? | TuHURA Biosciences' last 12 months net income is ($30M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.